Literature DB >> 1297640

Tolerance of ofloxacin in the treatment of pulmonary tuberculosis in presence of hepatic dysfunction.

W W Yew1, J Lee, P C Wong, S Y Kwan.   

Abstract

Twenty-nine patients with extensive pulmonary tuberculosis and drug-induced hepatitis were treated with ofloxacin along with other relatively non-hepatotoxic drugs, either during the interim phase to await recovery of liver function in some, or as definitive therapy as required by the compromised hepatic status of others. No adverse drug reactions were noted and no treatment failures were observed. This preliminary experience indicates the exceedingly good tolerance of ofloxacin when utilized in treatment of extensive pulmonary tuberculosis in the face of deranged liver function tests. Due to the small number of patients and numerous variables, no definite conclusion can be drawn on the specific efficacy of ofloxacin against Mycobacterium tuberculosis. However, it is concluded that acquisition of further clinical experience is warranted for similar patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1297640

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Res        ISSN: 0251-1649


  4 in total

Review 1.  Future directions in the development of new antitubercular drugs. Where do we go from here?

Authors:  W W Yew; C H Chau
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

2.  Effect of anti-tuberculosis therapy on liver function of pulmonary tuberculosis patients infected with hepatitis B virus.

Authors:  Lei Pan; Zhan-Sheng Jia; Lin Chen; En-Qing Fu; Guang-Yu Li
Journal:  World J Gastroenterol       Date:  2005-04-28       Impact factor: 5.742

Review 3.  Safety and tolerability profile of second-line anti-tuberculosis medications.

Authors:  Geetha Ramachandran; Soumya Swaminathan
Journal:  Drug Saf       Date:  2015-03       Impact factor: 5.606

Review 4.  Fluoroquinolones for the treatment of pulmonary tuberculosis.

Authors:  Susanne Moadebi; Curtis K Harder; Mark J Fitzgerald; Kevin R Elwood; Fawziah Marra
Journal:  Drugs       Date:  2007       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.